

Irinotecan

Essential medicine status

General description

Irinotecan is an antineoplastic topoisomerase I inhibitor used in the treatment of colorectal cancer.

INN

Irinotecan

ATC codes

[L01CE02](#)

Medicine type

Chemical agent

EML status history

First added in 2015 ([TRS 994](#)) for [Malignant neoplasm metastasis in large intestine](#)

Added in 2021 ([TRS 1035](#)) for [Malignant neoplasms of kidney, except renal pelvis](#)

Added in 2021 ([TRS 1035](#)) for [Rhabdomyosarcoma primary site](#)

Wikipedia

[Irinotecan](#)

DrugBank

[Irinotecan](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of kidney, except renal pelvis](#)

[Rhabdomyosarcoma primary site](#)